These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15143880)

  • 41. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
    JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effectiveness of adjuvant chemotherapy using gemcitabine for resected pancreatic cancer].
    Suzuki S; Morishita K; Kaji S; Koike N; Harada N; Takeo Y; Hayashi T; Suzuki M; Hanyu F
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):65-8. PubMed ID: 21368460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
    Ueno H; Kosuge T; Matsuyama Y; Yamamoto J; Nakao A; Egawa S; Doi R; Monden M; Hatori T; Tanaka M; Shimada M; Kanemitsu K
    Br J Cancer; 2009 Sep; 101(6):908-15. PubMed ID: 19690548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Oncological treatment of patients with pancreatic cancer].
    Ladekarl M; Jensen BV; Pfeiffer P
    Ugeskr Laeger; 2010 May; 172(18):1373-6. PubMed ID: 20444408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
    Hong GB; Zhou JX; Sun HB; Li CY; Song LQ
    Asian Pac J Cancer Prev; 2012; 13(6):2669-73. PubMed ID: 22938439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
    Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model.
    Lee NC; Bouvet M; Nardin S; Jiang P; Baranov E; Rashidi B; Yang M; Wang X; Moossa AR; Hoffma RM
    Clin Exp Metastasis; 2000; 18(5):379-84. PubMed ID: 11467769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
    Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
    Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
    Caponi S; Vasile E; Funel N; De Lio N; Campani D; Ginocchi L; Lucchesi M; Caparello C; Lencioni M; Cappelli C; Costa F; Pollina L; Ricci S; Mosca F; Falcone A; Boggi U
    Eur J Surg Oncol; 2013 Apr; 39(4):396-403. PubMed ID: 23290583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
    Abou-Alfa GK; Letourneau R; Harker G; Modiano M; Hurwitz H; Tchekmedyian NS; Feit K; Ackerman J; De Jager RL; Eckhardt SG; O'Reilly EM
    J Clin Oncol; 2006 Sep; 24(27):4441-7. PubMed ID: 16983112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
    Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
    Shimoda M; Kubota K; Shimizu T; Katoh M
    Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
    An SG; Kim DU; Song GA; Jang AL
    Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
    Ko AH; Quivey JM; Venook AP; Bergsland EK; Dito E; Schillinger B; Tempero MA
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):809-16. PubMed ID: 17363191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.